Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Hurry Up, STOP. . .Has CTA Been Struck Down By Courts?

Client Alert

On December 3, 2024, Judge Mazzant of the U.S. District Court for the Eastern District of Texas, Sherman Division, enjoined the Federal Government from enforcing the Corporate Transparency Act (CTA). To date, the case, Texas Top Cop Shop, Inc., et al v. Garland et al, No. 4:2024cv00478 - Document 30 (E.D. Tex. 2024), has garnered a lot of buzz.

Background
Following the passage of the CTA and effective January 1, 2024, many companies in the U.S. were slated to report information about their “beneficial owners” (individuals who ultimately own or control a company) to the Financial Crimes Enforcement Network (FinCEN), a bureau of the U.S. Department of the Treasury (Treasury). These reports are referred to as “BOI reports”. Under the CTA there are severe penalties for not timely and accurately filing the required BOI reports. As the December 31, 2024, initial filing deadline neared, attorneys, accountants and other advisors have been advising clients to get the filings completed.

Analysis
In Texas Top Cop, one private individual and five entities, including the aforementioned Texas Top Cop (a family-run, Texas corporation selling equipment to first responders), sought to enjoin the Federal Government from enforcing the CTA and its Implementing Regulations. It filed its lawsuit on May 28, 2024, seeking a declaratory judgment that the CTA is unconstitutional and an injunction against its enforcement. On October 9, 2024, the Court heard arguments from both the plaintiffs and defendants. In ruling for Texas Top Cop, the court agreed that the CTA intrudes upon States’ rights under the Ninth and Tenth Amendments, and is likely [emphasis added] outside of Congress’s power. What the court did not due was address whether the CTA compels speech and burdens the right of association under the First Amendment, and the CTA violates the Fourth Amendment by compelling disclosure of private information.

Fallout
Following Texas Top Cop, uncertainty has arisen regarding whether clients should file their BOI reports. After all, the Federal Government is enjoined from enforcing the CTA, right?

The answer depends.

Previously, on March 1, 2024, in National Small Business United v. Yellen, No. 5:22-cv-01448 (N.D. Ala. 2024), a federal district court in the Northern District of Alabama, Northeastern Division, entered a final declaratory judgment, concluding that the CTA exceeds the Constitution’s limits on Congress’s power and enjoined Treasury and FinCEN from enforcing the CTA. The difference between National Small Business United and Texas Top Cop is that National Small Business United applied solely to the plaintiffs who filed the case, while Texas Top Cop Shop applies to all.

In other cases outside of Texas, courts have declined to issue a nationwide injunction. See Small Business Association of Michigan et. al. v. Yellen et. al., No. 1:2024cv00314 (W.D. Mich. Apr. 26, 2024) (Michigan U.S. District Judge denies preliminary injunction of the CTA); Firestone v. Yellen, No. 3:24-cv-01034 (D. Or. June. 26, 2024) (Oregon U.S. District Judge declines to enjoin enforcement of the CTA); and Community Associations Institute v. Yellen, No. 1:24-cv-1597 (E.D. Va. Oct. 24, 2024) (Virginia U.S. District Judge denies preliminary injunction of the CTA).

What to do now?
After National Small Business United, the FinCEN website posted an alert reiterating that the final declaratory judgment only applied to the particular individuals and entities subject to the Northern District of Alabama’s injunction. It stressed that “reporting companies are still required to comply with the law and file beneficial ownership reports as provided in FinCEN’s regulations.” It will be interesting to see whether the FinCEN website will be updated in the coming days to address the Texas Top Cop injunction.

Regardless, enforcement of the CTA has been enjoined at least temporarily by the Texas Top Cop Shop case. While the federal government is likely to appeal the Texas decision, the changes in leadership at the Department of Justice resulting from the incoming Trump administration leaves the long-term status of the CTA uncertain.

To navigate this uncertain landscape, business owners are encouraged to consult with their BMD legal advisers or BMD Member Blake Gerney at brgerney@bmdllc.com.


Chevron Doctrine No More: What the Supreme Court’s Ruling Means for Agency Authority

On June 28, 2024, the Supreme Court invalidated the Chevron doctrine, nearly 40 years after it first took effect.

Ohio Board of Pharmacy Update: Key Regulatory Changes and Proposals You Need to Know

The Ohio Board of Pharmacy (BOP) has rescinded certain OAC rules (OAC 4729:5-18-01 through 4729:5-18-06), removing regulations on office-based opioid treatment (OBOT) clinics. The rescissions took effect on June 3, 2024. The BOP also published a new rule, OAC 4729:8-5-01, which sets explicit reporting guidelines for licensed dispensaries and became effective on June 7, 2024.

LGBTQIA+ Patients and Discrimination in Healthcare

In early April, the Kaiser Family Foundation released a study outlining the challenges that LGBT adults face in the United States related to healthcare. According to the study, LGBT patients are “twice as likely as non-LGBT adults to report negative experiences while receiving health care in the last three years, including being treated unfairly or with disrespect (33% v. 15%) or having at least one of several other negative experiences with a provider (61% v. 31%), including a provider assuming something about them without asking, suggesting they were personally to blame for a health problem, ignoring a direct request or question, or refusing to prescribe needed pain medication.”

Ohio Recovery Housing Overhaul: New Standards and Certification Requirements Reshape Sober Living Spaces

Ensuring Fair Access: SB 269 Protects Affordable Medication for Low-Income Patients

SB 269, introduced on December 19, 2023, will ensure that 340B covered entities, including Federally Qualified Health Centers, Ryan White Clinics, disproportionate share hospitals, and Title X clinics, can acquire 340B drugs without facing undue restrictions or discriminatory practices from drug manufacturers and distributors. This protection is crucial for 340B covered entities to continue to provide affordable medications and comprehensive services to low-income patients.